The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease

Hum Immunol. 2019 May;80(5):281-289. doi: 10.1016/j.humimm.2018.11.002. Epub 2018 Nov 9.

Abstract

The oxytocinase subfamily of M1 aminopeptidases plays an important role in processing and trimming of peptides for presentation on major histocompatibility (MHC) Class I molecules. Several large-scale genomic studies have identified association of members of this family of enzymes, most notably ERAP1 and ERAP2, with immune-mediated diseases including ankylosing spondylitis, psoriasis and birdshot chorioretinopathy. Much is now known about the genetics of these enzymes and how genetic variants alter their function, but how these variants contribute to disease remains largely unresolved. Here we discuss what is known about their structure and function and highlight some of the knowledge gaps that affect development of drugs targeting these enzymes.

Keywords: Aminopeptidase; Antigen presentation; Autoimmunity; Inhibitor.

Publication types

  • Review

MeSH terms

  • Aminopeptidases / antagonists & inhibitors
  • Aminopeptidases / chemistry
  • Aminopeptidases / genetics*
  • Aminopeptidases / metabolism*
  • Antigen Presentation
  • Autoimmunity
  • Biomarkers
  • Drug Development
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Genetic Predisposition to Disease
  • Humans
  • Immune System Diseases / diagnosis
  • Immune System Diseases / drug therapy
  • Immune System Diseases / etiology*
  • Immune System Diseases / metabolism*
  • Inflammation / diagnosis
  • Inflammation / etiology
  • Inflammation / metabolism
  • Inflammation / therapy
  • Models, Molecular
  • Molecular Targeted Therapy
  • Multigene Family
  • Polymorphism, Single Nucleotide
  • Protein Conformation
  • Structure-Activity Relationship

Substances

  • Biomarkers
  • Enzyme Inhibitors
  • Aminopeptidases